- Home
- H vs NEUP Comparison
H vs NEUP Comparison
Compare H & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- H
- NEUP
- Stock Information
- Founded
- H 1957
- NEUP 1996
- Country
- H United States
- NEUP United States
- Employees
- H N/A
- NEUP N/A
- Industry
- H Hotels/Resorts
- NEUP
- Sector
- H Consumer Discretionary
- NEUP
- Exchange
- H Nasdaq
- NEUP Nasdaq
- Market Cap
- H 15.1B
- NEUP 17.4B
- IPO Year
- H 2009
- NEUP N/A
- Fundamental
- Price
- H $140.11
- NEUP $4.88
- Analyst Decision
- H Buy
- NEUP Strong Buy
- Analyst Count
- H 17
- NEUP 1
- Target Price
- H $162.85
- NEUP $21.00
- AVG Volume (30 Days)
- H 835.0K
- NEUP 1.6M
- Earning Date
- H 02-13-2025
- NEUP 02-14-2025
- Dividend Yield
- H 0.43%
- NEUP N/A
- EPS Growth
- H 517.07
- NEUP N/A
- EPS
- H 12.65
- NEUP N/A
- Revenue
- H $3,296,000,000.00
- NEUP $662,715.00
- Revenue This Year
- H $117.48
- NEUP N/A
- Revenue Next Year
- H $5.97
- NEUP N/A
- P/E Ratio
- H $11.05
- NEUP N/A
- Revenue Growth
- H N/A
- NEUP N/A
- 52 Week Low
- H $128.91
- NEUP $2.12
- 52 Week High
- H $168.20
- NEUP $15.72
- Technical
- Relative Strength Index (RSI)
- H 32.55
- NEUP N/A
- Support Level
- H $141.52
- NEUP N/A
- Resistance Level
- H $147.52
- NEUP N/A
- Average True Range (ATR)
- H 5.52
- NEUP 0.00
- MACD
- H -2.01
- NEUP 0.00
- Stochastic Oscillator
- H 2.01
- NEUP 0.00
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (4% of total rooms) and managed and franchised (96%) properties across around 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 54% Americas, 22% rest of world, and 23% Asia-Pacific.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.